State-by-state data on United States COVID-19 vaccinations data

Acknowledgement and License

All data are produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited. In the case of our vaccination dataset, please give the following citation:

Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021). https://doi.org/10.1038/s41562-021-01122-8

Data Set Column Details

location : name of the state or federal entity. date: date of the observation. total vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. total vaccinations per hundred: total vaccinations per 100 people in the total population of the state. daily vaccinations raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily vaccinations instead. daily vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. daily vaccinations per million: daily vaccinations per 1,000,000 people in the total population of the state. people vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. people vaccinated per hundred: people vaccinated per 100 people in the total population of the state. people fully vaccinated: total number of people who received all doses prescribed by the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. people fully vaccinated per hundred: people fully vaccinated per 100 people in the total population of the state. total distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System. total distributed per hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state. share doses used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System. total boosters: total number of COVID-19 vaccination booster doses administered (doses administered beyond the number prescribed by the initial vaccination protocol) total boosters per hundred: total boosters per 100 people in the total population.

Time Span

20th Dec 2020 to 28th Dec 2022

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

As of March 20, 2023, over 13 billion COVID-19 vaccine doses had been administered worldwide, with the United States accounting for almost 672 million of this total. This statistic shows the number of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country.

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-ZIP-Code/2ani-ic5x. NOTE, 3/30/2023: We have added columns for bivalent (updated) doses to this dataset. We have also added age group columns for 0-17 and 18-64 and stopped updating the 5+ and 12+ columns, although previously published values remain for those columns. COVID-19 vaccinations administered to Chicago residents based on the home ZIP Code of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). The ZIP Code where a person lives is not necessarily the same ZIP Code where the vaccine was administered. Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. ·Total doses administered: Number of all COVID-19 vaccine doses administered. Data Notes: Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, and number of people who have received a bivalent dose. Cumulative totals for each measure as of that date are also provided. Vaccinations are counted based on the day the vaccine was administered. Coverage percentages are calculated based on cumulative number of people who have received at least one vaccine dose, cumulative number of people who have a completed vaccine series, and cumulative number of people who have received a bivalent dose in each ZIP Code. Population counts are from the U.S. Census Bureau American Community Survey 2015-2019 5-year estimates and can be seen in the ZIP Code, 2019 rows of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa). Actual counts may exceed population estimates and lead to >100% coverage, especially in areas with small population sizes. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination which may lead to over or under estimates of vaccination coverage by geography.  All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19. Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

Context

This dataset provides State-by-state data on United States COVID-19 vaccinations between 20 December of 2020 and 12 January of 2022. Data is taken daily by the United States Centers for Disease Control and Prevention

Columns

us_vaccinations File

- location: State name.

- date: date of the case.

- total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again.

- total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the state.

- daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead.

- daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here.

- daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the state.

- people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

- people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the state.

- people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

- people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the state.

- total_distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System.

- total_distributed_per_hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state.

- share_doses_used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System.

Data as of: May 18, 2021

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec.

COVID-19 vaccinations administered to Chicago residents based on home address, as reported by medical providers in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). I-CARE includes doses administered in Illinois and some doses administered outside of Illinois and reported in I-CARE by Illinois providers.

Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine.

·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received.

·People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19.

·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains.

·Total doses administered: Number of all COVID-19 vaccine doses administered.

Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, number of people with a monovalent booster dose, and number of people with a bivalent dose. Cumulative totals are also provided for each measure as of that date. Vaccinations are counted based on the day the vaccine was administered.

Coverage percentages for the City of Chicago are calculated based on cumulative number of people with that vaccination status.

Daily totals of all doses, number of people with at least one vaccine dose, number of people who have completed a vaccine series, number of people with a booster dose, and number of people with a bivalent dose are shown by age group, gender, and race/ethnicity.

Denominators are from the U.S. Census Bureau American Community Survey 1-year estimate for 2019 and can be seen in the Citywide, 2019 row of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa).

The Chicago Department of Health (CDPH) uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense, are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that can be linked to their record, such as someone receiving a vaccine dose in another state, the number of people with a completed series or a booster dose is underestimated. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate first dose records for a person and overestimate of the number of people with at least one dose and underestimate the number of people with a completed series or booster dose.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.https://www.hhs.gov/coronavirus/covid-19-vaccines/index.htmlPfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hggJanssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

Doses distributed and people initiating vaccination (1st dose received) are for both Moderna and Pfizer BioNTech COVID-19 vaccine and reflect current data available as of 9:00am ET on the day of reporting. Data will be regularly updated on Monday, Wednesday and Friday. Updates will occur the following day when reporting coincides with a federal holiday. Healthcare providers report doses to federal, state, territorial, and local agencies up to 72 hours after administration. There may be additional lag for data to be transmitted from the federal, state, territorial, or local agency to CDC. A large difference between the number of doses distributed and the number of people initiating vaccination is expected at this point in the COVID vaccination program due to several factors, including delays in reporting of administered doses and management of available vaccine stocks by jurisdictions and federal pharmacy partners. Numbers reported on CDC’s website are validated through a submission process with each jurisdiction and may differ from numbers posted on other websites. Differences between reporting jurisdictions and CDC’s website may occur due to the timing of reporting and website updates. The process used for reporting doses distributed or people vaccinated displayed by other websites may differ. When the “Rate per 100,000” metric is selected for both doses distributed and people initiating vaccination (1st dose received), federal entities will display as N/A because population-based rates are not applicable. Doses distributed and administered for federal entities will display as counts when the “Counts” metric is selected.

Data collected from Our World in Data's github repository which collects US vaccination data from the CDC. Includes vaccination progress of the US as a whole.

Description

• location: name of the state or federal entity.
• date: date of the observation.
• total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again.
• total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the state.
• daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead.
• daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here.
• daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the state.
• people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
• people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the state.
• people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
• people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the state.
• total_distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System.
• total_distributed_per_hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state.
• share_doses_used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System.

Acknowledgements

I'm not involved in the collecting and creation of this data; all credit goes to Our World in Data.

Questions

• Which states lead in vaccinating its residents?
• When will the US have a fully vaccinated population based on current rates?

Collected COVID-19 datasets from various sources as part of DAAN-888 course, Penn State, Spring 2022. Collaborators: Mohamed Abdelgayed, Heather Beckwith, Mayank Sharma, Suradech Kongkiatpaiboon, and Alex Stroud

**1 - COVID-19 Data in the United States ** Source: The data is collected from multiple public health official sources by NY Times journalists and compiled in one single file. Description: Daily count of new COVID-19 cases and deaths for each state. Data is updated daily and runs from 1/21/2020 to 2/4/2022. URL: https://github.com/nytimes/covid-19-data/blob/master/us-states.csv Data size: 38,814 row and 5 columns.

**2 - Mask-Wearing Survey Data ** Source: The New York Times is releasing estimates of mask usage by county in the United States. Description: This data comes from a large number of interviews conducted online by the global data and survey firm Dynata, at the request of The New York Times. The firm asked a question about mask usage to obtain 250,000 survey responses between July 2 and July 14, enough data to provide estimates more detailed than the state level. URL: https://github.com/nytimes/covid-19-data/blob/master/mask-use/mask-use-by-county.csv Data size: 3,142 rows and 6 columns

**3a - Vaccine Data – Global ** Source: This data comes from the US Centers for Disease Control and Prevention (CDC), Our World in Data (OWiD) and the World Health Organization (WHO). Description: Time series data of vaccine doses administered and the number of fully and partially vaccinated people by country. This data was last updated on February 3, 2022 URL: https://github.com/govex/COVID-19/blob/master/data_tables/vaccine_data/global_data/time_series_covid19_vaccine_global.csv
Data Size: 162,521 rows and 8 columns

**3b -Vaccine Data – United States ** Source: The data is comprised of individual State's public dashboards and data from the US Centers for Disease Control and Prevention (CDC). Description: Time series data of the total vaccine doses shipped and administered by manufacturer, the dose number (first or second) by state. This data was last updated on February 3, 2022. URL: https://github.com/govex/COVID-19/blob/master/data_tables/vaccine_data/us_data/time_series/vaccine_data_us_timeline.csv
Data Size: 141,503 rows and 13 columns

**4 - Testing Data ** Source: The data is comprised of individual State's public dashboards and data from the U.S. Department of Health & Human Services. Description: Time series data of total tests administered by county and state. This data was last updated on January 25, 2022. URL: https://github.com/govex/COVID-19/blob/master/data_tables/testing_data/county_time_series_covid19_US.csv
Data size: 322,154 rows and 8 columns

**5 – US State and Territorial Public Mask Mandates ** Source: Data from state and territory executive orders, administrative orders, resolutions, and proclamations is gathered from government websites and cataloged and coded by one coder using Microsoft Excel, with quality checking provided by one or more other coders. Description: US State and Territorial Public Mask Mandates from April 10, 2020 through August 15, 2021 by County by Day URL: https://data.cdc.gov/Policy-Surveillance/U-S-State-and-Territorial-Public-Mask-Mandates-Fro/62d6-pm5i Data Size: 1,593,869 rows and 10 columns

**6 – Case Counts & Transmission Level ** Source: This open-source dataset contains seven data items that describe community transmission levels across all counties. This dataset provides the same numbers used to show transmission maps on the COVID Data Tracker and contains reported daily transmission levels at the county level. The dataset is updated every day to include the most current day's data. The calculating procedures below are used to adjust the transmission level to low, moderate, considerable, or high.
Description: US State and County case counts and transmission level from 16-Aug-2021 to 03-Feb-2022 URL: https://data.cdc.gov/Public-Health-Surveillance/United-States-COVID-19-County-Level-of-Community-T/8396-v7yb Data Size: 550,702 rows and 7 columns

**7 - World Cases & Vaccination Counts ** Source: This is an open-source dataset collected and maintained by Our World in Data. OWID provides research and data to help against the world’s largest problems.
Description: This dataset includes vaccinations, tests & positivity, hospital & ICU, confirmed cases, confirmed deaths, reproduction rate, policy responses and other variables of interest. URL: https://github.com/owid/covid-19-data/tree/master/public/data Data Size: 67 columns and 157,000 rows

**8 - COVID-19 Data in the European Union ** Source: This is an open-source dataset collected and maintained by ECDC. It is an EU agency aimed at strengthening Europe's defenses against infectious diseases.
Description: This dataset co...

Expected number of incremental infections and deaths avoided in the U.S. under different trial designs, vaccine efficacies, and epidemiological scenarios, assuming trials start on August 1, 2020, superiority testing, and 10M doses of a vaccine per day are available after licensure, compared to the baseline case in which no vaccine is ever approved.

How many people have received a coronavirus vaccine?

Tracking COVID-19 vaccination rates is crucial to understand the scale of protection against the virus, and how this is distributed across the global population.

A global, aggregated database on COVID-19 vaccination rates is essential to monitor progress, but it is unfortunately not yet available. This dataset provides the last weekly update of vaccination rates.

Last update

June 2021

Content

Colums description: 1. iso_code: ISO 3166-1 alpha-3 – three-letter country codes 2. continent: Continent of the geographical location 3. location: Geographical location 4. date: Date of observation 5. total_cases: Total confirmed cases of COVID-19 6. new_cases: New confirmed cases of COVID-19 7. new_cases_smoothed: New confirmed cases of COVID-19 (7-day smoothed) 8. total_deaths: Total deaths attributed to COVID-19 9. new_deaths: New deaths attributed to COVID-19 10. new_deaths_smoothed: New deaths attributed to COVID-19 (7-day smoothed) 11. total_cases_per_million: Total confirmed cases of COVID-19 per 1,000,000 people 12. new_cases_per_million: New confirmed cases of COVID-19 per 1,000,000 people 13. new_cases_smoothed_per_million: New confirmed cases of COVID-19 (7-day smoothed) per 1,000,000 people 14. total_deaths_per_million: Total deaths attributed to COVID-19 per 1,000,000 people 15. new_deaths_per_million: New deaths attributed to COVID-19 per 1,000,000 people 16. new_deaths_smoothed_per_million: New deaths attributed to COVID-19 (7-day smoothed) per 1,000,000 people 17. reproduction_rate: Real-time estimate of the effective reproduction rate (R) of COVID-19. See http://trackingr-env.eba-9muars8y.us-east-2.elasticbeanstalk.com/FAQ 18. icu_patients: Number of COVID-19 patients in intensive care units (ICUs) on a given day 19. icu_patients_per_million: Number of COVID-19 patients in intensive care units (ICUs) on a given day per 1,000,000 people 20. hosp_patients: Number of COVID-19 patients in hospital on a given day 21. hosp_patients_per_million: Number of COVID-19 patients in hospital on a given day per 1,000,000 people 22. weekly_icu_admissions: Number of COVID-19 patients newly admitted to intensive care units (ICUs) in a given week 23. weekly_icu_admissions_per_million: Number of COVID-19 patients newly admitted to intensive care units (ICUs) in a given week per 1,000,000 people 24. weekly_hosp_admissions: Number of COVID-19 patients newly admitted to hospitals in a given week 25. weekly_hosp_admissions_per_million: Number of COVID-19 patients newly admitted to hospitals in a given week per 1,000,000 people 26. total_tests: Total tests for COVID-19 27. new_tests: New tests for COVID-19 28. new_tests_smoothed: New tests for COVID-19 (7-day smoothed). For countries that don't report testing data on a daily basis, we assume that testing changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window 29. total_tests_per_thousand: Total tests for COVID-19 per 1,000 people 30. new_tests_per_thousand: New tests for COVID-19 per 1,000 people 31. new_tests_smoothed_per_thousand: New tests for COVID-19 (7-day smoothed) per 1,000 people 32. tests_per_case: Tests conducted per new confirmed case of COVID-19, given as a rolling 7-day average (this is the inverse of positive_rate) 33. positive_rate: The share of COVID-19 tests that are positive, given as a rolling 7-day average (this is the inverse of tests_per_case) 34. tests_units: Units used by the location to report its testing data 35. total_vaccinations: Number of COVID-19 vaccination doses administered 36. total_vaccinations_per_hundred: Number of COVID-19 vaccination doses administered per 100 people 37. stringency_index: Government Response Stringency Index: composite measure based on 9 response indicators including school closures, workplace closures, and travel bans, rescaled to a value from 0 to 100 (100 = strictest response) 38. population: Population in 2020 39. population_density: Number of people divided by land area, measured in square kilometers, most recent year available 40. median_age: Median age of the population, UN projection for 2020 41. aged_65_older: Share of the population that is 65 years and older, most recent year available 42. aged_70_older: Share of the population that is 70 years and older in 2015 43. gdp_per_capita: Gross domestic product at purchasing power parity (constant 2011 international dollars), most recent year available 44. extreme_poverty: Share of the population living in extreme poverty, most recent year available since 2010 45. cardiovasc_death_rate: Death rate from cardiovascular disease in 2017 (annual number of deaths per 100,000 people) 46. diabetes_prevalence: Diabetes prevalence (% of population aged 20 to 79) in 2017 47. female...

The Covid-19 curve in the United States is rising again after months of decline, with the number of new cases per day doubling over the past three weeks, driven by the fast-spreading Delta variant, lagging vaccination rates, and Fourth of July gatherings

In the United States of America, from 3 January 2020 to 5:05 pm CEST, 14 July 2021, there have been 33,572,715 confirmed cases of COVID-19 with 602,409 deaths, reported to WHO. As of 9 July 2021, a total of 334,282,915 vaccine doses have been administered.

Content

This Column is a resource to help advance the understanding of the virus all-state in the USA

As of January 23, 2021, Vermont had the highest Rt value of any U.S. state. The Rt value indicates the average number of people that one person with COVID-19 is expected to infect. A number higher than one means each infected person is passing the virus to more than one other person.

Which are the hardest-hit states? The U.S. reported its first confirmed coronavirus case toward the end of January 2020. More than 28 million positive cases have since been recorded as of February 24, 2021 – California and Texas are the states with the highest number of coronavirus cases in the United States. When figures are adjusted to reflect each state’s population, North Dakota has the highest rate of coronavirus cases. The vaccine rollout has provided Americans with a significant morale boost, and California is the state with the highest number of COVID-19 vaccine doses administered.

How have other nations responded? Countries around the world have responded to the pandemic in varied ways. The United Kingdom has approved three vaccines for emergency use and ranks among the countries with the highest number of COVID-19 vaccine doses administered worldwide. In the Asia-Pacific region, the outbreak has been brought under control in New Zealand, and the country’s response to the pandemic has been widely praised.

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

As of March 16, 2022, there was a total of approximately 5.9 million confirmed cases of coronavirus disease (COVID-19) in Japan, with around 529 thousand people needing inpatient treatment.

Development of cases in Japan Generally, the increase of new COVID-19 cases recorded from January to March 2020 in Japan followed a slower trajectory as compared to, for example, China, Europe, or the United States of America. The first reported case of COVID-19 in Japan was confirmed on January 16, 2020, when a man that had returned from Wuhan city, China, was tested positive. The first transmission within Japan was recorded on January 28. The number of new cases then increased tenfold in February. April saw a further acceleration of the infection rate. Consequently, the Japanese government declared a nationwide state of emergency that month. The government announced a state of emergency for the second time in January 2021, the third time in April 2021, and the forth time in the July 2021.

Vaccine rollout The Japanese government started the distribution of COVID-19 vaccination in February 2021, mainly for medical professionals. The administration of vaccination for general citizens commenced in April for senior citizens. The vaccine rate of the population was just over 74.7 percent for second doses as of March 2022.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figure page. 

Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed novel antigens based on the Beta & Delta variants of concern. These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity to all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing variants of concern, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants. Methods Antigens SmT1v3-R, -B and –D constructs are based on SARS-CoV-2 spike trimers described previously22,23 but with C-terminal FLAG/His affinity tags removed. Briefly, the SARS-CoV-2 reference strain spike ectodomain sequence (amino acids 1-1208 derived from Genbank accession number MN908947) was codon-optimized for Chinese Hamster Ovary (CHO) cells and synthesized by GenScript. Within the construct, the spike glycoprotein was preceded by its natural N-terminal signal peptide and fused at the C-terminus to human resistin (accession number NP_001180303.1, amino acids 23-108). Mutations were added to stabilize the generated spike protein as previously described; amino acids 682-685 (RRAR) and 986-987 (KV) were replaced with GGAS and PP, respectively24,25. Constructs were then cloned into the pTT241 plasmid. Expression constructs for VOC spike variants were prepared by re-synthesizing and replacing restriction fragments encompassing mutations present in the Beta (SmT1v3-B) (D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V) and Delta (SmT1v3-D) (T19R, G142D, E156-, F157-, R158G, L452R, T478K, D614G, P681R, D950N) variants, while maintaining the codon-optimized sequences of the remaining amino acids used for SmT1v3-R expression. Stably transfected pools were established by MSX selection using the CHO2353™ cell line and used for 10-day fed-batch productions with cumate induction as described23. Spike proteins were purified using a proprietary multi-step non-affinity-based process and formulated in Dulbecco’s Phosphate Buffered Saline (DPBS; Hyclone, Logan, Utah, USA) adjusted to pH 7.8 at protein concentrations of 1.1-1.4 mg/ml. Purified proteins analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analytical size-exclusion ultra-high performance liquid chromatography (SEC-UPLC). SEC-UPLC was run on an Acquity H-Class Bio UPLC system (Wyatt Technology, Santa Barbara, CA, USA) in phosphate-buffered saline (PBS) + 0.02% Tween-20 on a 4.6 × 300 mm Acquity BEH450 column (2.5 μm bead size; Waters Limited, Mississauga, ON, Canada) coupled to a miniDAWN Multi-Angle Light Scattering (MALS) detector and Optilab T-rEX refractometer (Wyatt). The identity and purity of the antigens was also confirmed by mass spectrometry. Absence of endotoxin contamination was verified using Endosafe cartridge-based Limulus amebocyte lysate tests (Charles River Laboratories, Charleston, SC, USA). Immunization & sample collection Female C57BL/6 mice (6-8 weeks old) were obtained from Charles River Laboratories (Saint-Constant, Canada). Animals were maintained at the small animal facility of the National Research Council Canada (NRC) in accordance with the guidelines of the Canadian Council on Animal Care. All procedures performed on animals in this study were approved by our Institutional Review Board (NRC Human Health Therapeutics Animal Care Committee) and covered under animal use protocol 2020.10. All experiments were carried out in accordance with the ARRIVE guidelines. Mouse experiments (n=10 per group) consisted of 2 separate equal-sized cohorts, where animals were treated identically but had procedures conducted on different days. Data from both cohorts was combined and included for analysis. Seven out of a total of 70 mice receiving AddaS03-adjuvanted formulations had to be excluded due to high local reactogenicity at the site of injection. As such, the AddaS03 groups had 9-10 mice per group included in the final analysis, except for one group (1 µg SmT1v3-R) where results from 7 mice were included. Antigen and adjuvant vaccine components were admixed and diluted in phosphate-buffered saline (PBS; Thermo Fisher Scientific, Waltham, MA, USA) prior to administration in a final volume of 50 µL per dose. Sulfated lactosyl archaeol (SLA) archaeosomes are proprietary NRC adjuvants that were prepared as previously described26. Levels of endotoxin in the SLA archaeosomes were verified by the Endosafe® cartridge-based Limulus amebocyte lysate test (Charles River Laboratories) and confirmed to be <0.1 EU per mg. AddaS03 (Invivogen, San Diego, CA, USA) was prepared as per manufacturer’s instructions. Animals were immunized by intramuscular (i.m.) injection (50 µL) into the left tibialis anterior (T.A.) muscle on Days 0 and 21 with various vaccine formulations as described above. On Day 28, mice were anesthetized with isoflurane and then euthanized by cervical dislocation prior to collection of spleens for measurement of cellular immune responses by IFN-γ ELISpot. Mice were bled via the submandibular vein on Days 20 and 28 with recovered serum used for quantification of antigen-specific IgG antibody levels and neutralization assays. Samples were simultaneously collected from 10 naïve animals for the assessment of background immune responses. Each of the samples from the individual mice was tested separately in the various readouts. Anti-Spike IgG ELISA Anti-spike total IgG titers in serum were measured by indirect ELISA with SmT1-R, -B or -D as previously described10. Briefly, 96–well high-binding ELISA plates (Thermo Fisher Scientific) were coated with 0.3 µg/mL SmT1 protein diluted in PBS. Serum samples were serially diluted 3.162-fold and added to the plates to allow for binding of antibodies to the protein. Bound IgG was detected with goat anti-mouse IgG -HRP (1:4,000, Southern Biotech, Birmingham, AL, USA) prior to the addition of the substrate o-phenylenediamine dihydrochloride (OPD, Sigma-Aldrich). Bound IgG Abs were detected spectrophotometrically at 450 nm. Titers for IgG in serum were defined as the dilution that resulted in an absorbance value (OD450) of 0.2 and were calculated using XLfit software (ID Business Solutions, Guildford, UK). Samples that did not reach the target OD were assigned the value of the lowest tested dilution (i.e. 100) for analysis purposes. No detectable titers were measured in serum samples from naïve control animals. IFN- γ ELISpot IFN- γ ELISpot was also conducted as previously described10. The levels of spike glycoprotein-specific T cells were quantified by ELISpot using a mouse IFN-γ kit (Mabtech Inc., Cincinnati, OH, USA). A spike peptide library (JPT Peptide Technologies GmbH) based on the reference strain sequence and consisting of 315 peptides (15mers overlapping by 11 amino acids with the last peptide consisting of a 17mer) was used to stimulate splenocytes isolated from each of the mice. The library was split into 3 subpools and used to separately stimulate 4x105 cells in duplicate at a final concentration of 2 µg/mL per peptide. Cells were also incubated without any stimulants to measure background responses. Spots were counted using an automated ELISpot plate reader (Cellular Technology LTD, Beachwood, OH, USA). For each animal, values obtained with media alone were subtracted from those obtained with each of the spike peptide pools and then combined to yield an overall number of antigen-specific IFN-γ+ SFC/106 splenocytes per animal.
Cell-based SARS CoV-2 Spike-ACE2 Binding Assay The ability serum to neutralize the binding of labeled SARS-CoV-2 spike trimers (SmT1) to Vero E6 cells was measured as previously described10. Indicated dilutions of mouse serum were mixed with 250 ng of biotinylated spike and 1x105 Vero E6 cells (ATCC® CRL-1586™). The amount of bound spike was quantified using a Streptavidin-phycoerythrin conjugate prior to acquisition on an LSR Fortessa (Becton Dickinson). For analysis purposes, samples with calculated values ≤ 0 were assigned a value of 0. The levels of neutralization were normalized to the World Health Organization human standard reference material (20/136 from NIBSC, South Mimms, UK) to obtain the anti-SARS-CoV-2 activity (IU/mL) in undiluted mouse serum. Pseudovirus Neutralization Assay Pseudovirus neutralization assay was performed in 384-well plate format adapted from previously described protocol and modification27,28. Briefly, 4-fold serial dilutions of the serum samples were incubated with diluted virus at a 2:1 ratio for 1 hour at 37°C before addition to HEK293-ACE2/TMPRSS2 cells obtained from BEI Resources repository of ATCC and the NIH (NR-55293). Infectivity was then measured by luminescence readout per well. Bright-Glo luciferase reagent (Promega, E2620) was added to wells for 2 min before reading with a PerkinElmer Envision instrument. Neutralization Titer 50 (NT50) were calculated with nonlinear regression (log[inhibitor] versus normalized response – variable slope) with the 100% and 0% constraint. Pseudotyped lentiviral particles were produced expressing the SARS-CoV-2 variant spikes under CMV promotor and were packaged onto lentiviral vectors obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Wuhan-Hu-1 (GenBank # NC_045512) Spike-Pseudotyped Lentiviral Kit, NR-52948. pcDNA3.3-SARS2-B.1.617.2 expressing the SARS-CoV-2 B.1.617.2 (Delta variant) (Addgene plasmid # 172320) and pcDNA3.3_CoV2_501V2 expressing SARS-CoV-2, B.1.351 (Beta variant) (Addgene plasmid # 170449) spike proteins were gifts from David Nemazee. Statistical analysis Data were analyzed using GraphPad Prism® version 8 (GraphPad Software). Statistical significance of the difference

This study aimed to identify the most influential age groups in COVID-19 infection rates at the US county level using the Modified Morris Method and deep learning for time series. The approach involved training the state-of-the-art time-series model Temporal Fusion Transformer on different age groups as a static feature and the population vaccination status as the dynamic feature. The impact of those age groups was analyzed on COVID-19 infection rates by perturbing individual input features and ranked them based on their Morris sensitivity scores, which quantify their contribution to COVID-19 transmission rates. The data contains the population by age subgroups for each of the 3,142 US counties, along with the daily vaccination rate of the population and COVID-19 case report from March 1, 2020, to Dec 27, 2021. The eight age subgroups are 0-4, 5-17, 18-29, 30-39, 40-49, 50-64, 65-74, and 75 and older for all counties.

Features

The following table lists the features with their source and description. Note that, past values of the target and known futures are also used as observed inputs by TFT.

Vaccine A mimics BNT162b2 (Pfizer & BioNTech); vaccine B mRNA-1273 (Moderna) and vaccine C ChAdOx1 nCoV-2019 (University of Oxford/AstraZeneca). The source for the estimates are: [53–55].